The Food and Drug Administration is adding a boxed warning about the risk of an allergic reaction for Teva‘s (TEVA) Copaxone and Sandoz’s (SDZNY) Glatopa, which are used to treat patients with multiple sclerosis. A serious allergic reaction, called anaphylaxis, can occur at any time while on treatment, after the first dose or after doses administered months or years after starting the medicine, the agency said in a statement.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
- Teva price target raised to $30 from $23 at Piper Sandler
- Teva call volume above normal and directionally bullish
- Teva enters pact with Klinge Biopharma, Formycon to commercialize FYB203
- Teva, Samsung Bioepis enter partnership for commercialization of EPYSQLI
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue